9 results about "Stage melanoma" patented technology

The application provides application of a C1q neutralizing monoclonal antibody combined with a PD-1 monoclonal antibody in preparation of a drug for treating a solid tumor, and belongs to the technical field of biological medicine. It is found that the combination of the C1q neutralizing monoclonal antibody and the PD-1 monoclonal antibody can effectively enhance the anti-tumor effect on the solid tumor, and especially exhibits a significant synergistic inhibitory effect on the growth and metastasis of a solid tumor resistant to the PD-1 monoclonal antibody, wherein the solid tumor resistant to the PD-1 monoclonal antibody includes but is not limited to colorectal cancer, melanoma, lung adenocarcinoma and liver cancer. The application provides a new treatment option for patients resistant to the PD-1 monoclonal antibody, and has a wide clinical application prospect.

The application discloses a 3'-deoxyadenosine compound and application thereof in preparation of an antitumor drug. The 3'-deoxyadenosine compound and the pharmaceutical composition thereof have good antitumor proliferation effect. Compared with a parent drug, the 3'-deoxyadenosine compound has better affinity to a cell membrane, so that the half-life of in-vivo metabolism of the drug is longer, and the drug stays in the body for a longer time. Compared with other nucleoside antitumor drugs, the cordycepin derivative and the pharmaceutical composition thereof have a wider range of tumor types and effects, including excellent inhibition effect on gastric cancer, pancreatic cancer, liver cancer, small cell lung cancer, colorectal cancer, melanoma, ovarian cancer and the like, and the side effect is lower and the curative effect is better.

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.

This invention relates to a compound and its preparation method, a modular peptide nanovaccine and its preparation method and application, and relates to the pharmaceutical field. The chemical structural formula of the compound is shown in Formula I. This invention provides a compound containing an mPEG-PLA structure, a protoporphyrin structure chelated with cobalt ions, and a β-cyclodextrin structure, endowing it with excellent binding ability to peptides and excellent loading capacity with adjuvants, achieving co-delivery of peptides and adjuvants. Based on this, this invention also provides a modular peptide nanovaccine with high peptide loading rate and "plug-and-play" characteristics. It can significantly inhibit tumor growth in a B16 subcutaneous tumor model, providing an efficient and flexible technical platform for the prevention of melanoma and other tumors and the clinical translation of peptide vaccines, with broad application prospects.

The present application relates to the use of [10]-shogaol in the preparation of a medicament for preventing and / or treating tumors sensitive to ferroptosis. Specifically, the present application provides a method for screening ferroptosis inducers, comprising the following steps: taking cells sensitive to ferroptosis, applying a candidate compound to a test group, applying [10]-shogaol to a positive control group, applying [6]-shogaol to a non-ferroptosis inducer group, and not applying any compound to a blank control group; detecting the lipid peroxidation level in the cells of each group; comparing the lipid peroxidation levels of the test group and the other groups to detect whether the candidate compound is a ferroptosis inducer. The [10]-shogaol can effectively induce ferroptosis in various malignant tumor cells such as breast cancer, colorectal cancer, melanoma, etc., and the mechanism of action depends on the accumulation of lipid peroxidation, and this effect can be specifically blocked by ferroptosis inhibitors.

The application relates to the technical field of melanoma prognosis, and provides a construction method and a verification method of a melanoma prognosis model based on a lactation gene methylation feature. The DNA methylation data of a cancer genome atlas database is taken as a training set, and the DNA methylation data of a gene expression comprehensive database is taken as a verification set, so that the lactation-related gene methylation feature prognosis marker model of melanoma constructed has good external applicability. A methylation site pair matrix is constructed through the relative methylation order relationship of the methylation sites, so that the batch effect between different data sets is effectively avoided, and excellent robustness and clinical applicability are achieved. The methylation sites corresponding to the lactation-related gene set are taken as anchor points to perform hierarchical clustering and differential methylation site screening, functional sites related to prognosis are screened out, the reliability of the constructed prognosis marker model is improved, and the accuracy of prognosis prediction is improved.

This invention discloses a heparin-like hydrogel microsphere for melanoma postoperative wound repair, its preparation method, and its application, belonging to the field of medical dressing technology. The preparation of the heparin-like hydrogel microsphere for melanoma postoperative wound repair includes the following steps: dissolving KOSMA and GelMA in water to prepare a GelMA solution; adding a photoinitiator to form a precursor hydrogel solution; using the precursor hydrogel solution as the dispersed phase and castor oil as the continuous phase to prepare hydrogel microspheres; collecting the effluent; exposing it to ultraviolet light for curing; washing; and drying to obtain the final product. When used for melanoma postoperative wound care, these hydrogel microspheres can safely promote wound healing, specifically eliminate residual tumor cells, reduce the postoperative local recurrence rate, and can also serve as drug carriers to achieve synergistic therapeutic effects; providing new research ideas and technical strategies for integrated care of melanoma postoperative wounds and tumor prevention and control.

The application relates to the biomedical technology field and discloses application of BAZ2B gene as a target point in inhibition of drug efflux of tumor cells. The application successfully proves for the first time that an inhibitor of the BAZ2B gene or a coded protein has an inhibiting effect on the efflux of nanometer materials such as Au, SiO2 and micelles in cells. The efflux of FB@SR micelle nanometer materials to tumor cells (such as melanoma cells) is reduced by inhibiting the BAZ2B gene, and the boron content in the cells is increased. The FB@SR is used as a new type of boron delivery agent, and compared with cells without BAZ2B gene silencing, the boron content in the cells is increased after the BAZ2B gene is silenced, the BNCT treatment window is prolonged, and better and higher-quality treatment effects are obtained.

This invention discloses a small molecule peptide derived from *Hirudo medicinalis*, with the amino acid sequence Leu-Leu-Phe-Arg. The peptide was obtained by enzymatically hydrolyzing the waste protein residue after purifying hirudin from *Hirudo medicinalis*, combined with tyrosinase-functionalized magnetic bead affinity fishing technology and mass spectrometry identification. In vitro kinetics and molecular dynamics simulations confirmed that the peptide LLFR significantly prolongs the lag time of monophenolase reactions. It penetrates the catalytic pocket of tyrosinase through an "induced fit" mechanism, forming a stable dead-end complex with the enzyme and inducing the unfolding of the enzyme's tertiary structure. Cell experiments confirmed that LLFR significantly inhibits tyrosinase activity and melanin synthesis in melanoma cells without significant cytotoxicity. This peptide exhibits high safety and good water solubility, providing a new approach for the high-value utilization of industrial waste from *Hirudo medicinalis*, and is suitable for the industrial production of whitening cosmetics and functional products.